Amsterdam, NL – argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has… Read More
CHICAGO – Aon a leading global professional services firm, released updated findings from its multi-year study of U.S. commercial health claims data, building on its GLP-1 research first released in April 2025. Drawing on medical… Read More
RYBELSUS® (semaglutide tablets) is the first glucagon-like peptide-1 (GLP-1) approved in Canada to reduce the risk of major adverse cardiovascular events (MACE.) RYBELSUS® (semaglutide tablets) is approved to reduce the… Read More
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in… Read More
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver… Read More
